Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce that the US Centers for Medicare & Medicaid Services has published its final determination of the national reimbursement price in the United States for the PromarkerD predictive test for diabetic kidney disease.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to provide an opportunity for shareholders and investors to view a virtual presentation by Managing Director Dr Richard Lipscombe.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of its latest investor presentation for a non-deal roadshow to institutional investors.
Proteomics International Laboratories Ltd (ASX:PIQ), a medical technology company at the forefront of precision medicine and predictive diagnostics, is pleased to provide the following update on its business activities for the three months to 30 September 2023 and subsequent to the period end.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to invite shareholders, investors and interested parties to an online update on the recent announcement regarding the PromarkerD US Reimbursement Price.